Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.34
    -0.43 (-5.53%)

    Market Cap: $401.70M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Puma Biotechnology Inc (PBYI) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Puma Biotechnology (PBYI) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Puma Biotechnology reported EPS of $0.11, above the $0.06 estimate. It beat the EPS estimate in each of the last 11 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    82%(32/39)
    Avg Surprise
    +90.02%
    Streak
    11 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.23
    Range$0.23 - $0.24
    3 analysts
    Revenue Consensus
    $68.54M
    Range$65.86M - $70.56M
    3 analysts

    Next Report

    PBYI has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 11.5% below the $0.26 reported for the quarter ended Dec 31, 2025.

    PBYI Earnings Call

    The latest PBYI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, PBYI beat 32 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $55.06M, up 1.1% from $54.48M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.11$0.06N/A+83.33%Beat-47.6%10 up, 0 downNov 5, 2026$55.06M
    Jun 30, 2026$0.16$0.06N/A+166.67%Beat+33.3%10 up, 0 downAug 6, 2026$56.50M
    Mar 31, 2026-$0.04-$0.13-$0.13 - -$0.13+69.23%Beat-166.7%10 up, 0 downMay 7, 2026$44.81M
    Dec 31, 2025$0.26$0.19N/A+36.84%Beat-39.5%11 up, 0 downFeb 26, 2026$75.45M
    Sep 30, 2025$0.21$0.09$0.09 - $0.09+133.33%Beat-53.3%10 up, 1 downNov 6, 2025$54.48M
    Jun 30, 2025$0.12$0.08N/A+50.00%BeatN/A10 up, 1 downAug 7, 2025$52.44M
    Mar 31, 2025$0.06-$0.02N/A+400.00%BeatN/A20 up, 0 downMay 8, 2025$46.01M
    Dec 31, 2024$0.43$0.14$0.13 - $0.15+207.14%Beat+65.4%21 up, 0 downFeb 27, 2025$59.08M
    Sep 30, 2024$0.45$0.38$0.31 - $0.41+18.42%Beat+164.7%31 up, 0 downNov 7, 2024$80.54M
    Jun 30, 2024-$0.05-$0.10-$0.19 - -$0.08+50.00%Beat-150.0%30 up, 1 downAug 1, 2024$47.08M
    Mar 31, 2024-$0.05-$0.15N/A+66.67%Beat-155.6%30 up, 0 downMay 2, 2024$43.77M
    Dec 31, 2023$0.26$0.30$0.27 - $0.35-13.33%MissN/A30 up, 0 downFeb 29, 2024$72.18M
    Sep 30, 2023$0.17$0.14N/A+21.43%Beat+240.0%30 up, 0 downNov 2, 2023$56.12M
    Jun 30, 2023$0.10$0.07N/A+42.86%Beat-64.3%40 up, 0 downAug 3, 2023$54.57M
    Mar 31, 2023$0.09-$0.01N/A+1000.00%BeatN/A31 up, 0 downMay 4, 2023$52.77M
    Dec 31, 2022-$0.12$0.01-$0.08 - $0.05N/AN/A-220.0%30 up, 0 downMar 2, 2023$58.64M
    Sep 30, 2022$0.05$0.03N/A+66.67%BeatN/A31 up, 0 downNov 3, 2022$57.10M
    Jun 30, 2022$0.28$0.09N/A+211.11%Beat-12.5%N/A0 up, 0 downAug 4, 2022$59.52M
    Mar 31, 2022-$0.01-$0.11N/A+90.91%Beat-101.8%51 up, 0 downMay 5, 2022$45.74M
    Dec 31, 2021$0.10-$0.09-$0.22 - $0.19+211.11%BeatN/A50 up, 0 downMar 3, 2022$55.36M
    Sep 30, 2021-$0.99-$0.22-$0.51 - -$0.18-350.00%MissN/A6N/ANov 4, 2021$46.24M
    Jun 30, 2021$0.32-$0.14-$0.40 - $0.01+328.57%Beat-8.6%7N/AAug 5, 2021$53.38M
    Mar 31, 2021$0.55$0.34-$0.79 - $0.39+61.76%BeatN/A7N/AMay 6, 2021$98.17M
    Dec 31, 2020-$0.38-$0.31-$0.71 - $0.19-22.58%Miss-3900.0%9N/AFeb 25, 2021$52.56M
    Sep 30, 2020-$0.60-$0.14N/A-328.57%MissN/A10N/ANov 5, 2020$50.75M
    Jun 30, 2020$0.35$0.14-$0.53 - $0.16+150.00%BeatN/A11N/AAug 6, 2020$70.58M
    Mar 31, 2020-$0.20-$0.68-$0.97 - -$0.42+70.59%Beat-200.0%10N/AMay 7, 2020$51.22M
    Dec 31, 2019$0.01-$0.26N/A+103.85%BeatN/A10N/AFeb 20, 2020$9.00M
    Sep 30, 2019-$0.12-$0.45N/A+73.33%Beat-175.0%9N/ANov 6, 2019$56.35M
    Jun 30, 2019-$0.57-$0.89-$1.37 - -$0.74+35.96%BeatN/A9N/AAug 8, 2019$107.84M
    Mar 31, 2019$0.20-$0.20N/A+200.00%Beat+900.0%9N/AMay 9, 2019$99.07M
    Dec 31, 2018-$0.80-$0.77-$1.02 - -$0.50-3.90%MissN/A9N/AFeb 28, 2019$71.08M
    Sep 30, 2018$0.16-$0.45N/A+135.56%BeatN/A8N/ANov 1, 2018$62.63M
    Jun 30, 2018-$0.59-$0.82N/A+28.05%BeatN/A5N/AAug 9, 2018$50.77M
    Mar 31, 2018$0.02-$0.31-$1.77 - -$0.31+106.45%BeatN/A6N/AMay 9, 2018$66.52M
    Dec 31, 2017-$1.71-$1.97-$2.25 - -$1.65+13.20%BeatN/A7N/AMar 1, 2018$21.61M
    Sep 30, 2017-$1.36-$1.42N/A+4.23%BeatN/A7N/ANov 9, 2017$6.08M
    Jun 30, 2017-$1.38-$1.31N/A-5.34%MissN/A7N/AAug 9, 2017N/A
    Mar 31, 2017-$1.16-$1.20N/A+3.33%BeatN/AN/AN/AMay 10, 2017N/A
    Dec 31, 2016-$2.04-$1.92N/A-6.25%MissN/AN/AN/AMar 1, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.65, down 16.7% from the year before. It was -$5.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.65-16.7%
    Dec 31, 2024$0.78+25.8%
    Dec 31, 2023$0.62+210.0%
    Dec 31, 2022$0.20N/A
    Dec 31, 2021-$0.02N/A
    Dec 31, 2020-$0.83N/A
    Dec 31, 2019-$0.48N/A
    Dec 31, 2018-$1.21N/A
    Dec 31, 2017-$5.61N/A
    Dec 31, 2016-$5.60N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,800 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,7756
    2026Q2Jun 30, 20264,2277
    2026Q1Mar 31, 20268,2867
    2025Q4Dec 31, 20254,4177
    2025Q3Sep 30, 20254,6027
    2025Q2Jun 30, 20254,5657
    2025Q1Mar 31, 20255,2279
    2024Q3Sep 30, 20245,4278

    2026Q3 Earnings Call

    Opening remarks

    Mariann Ohanesian Senior Director of Investor Relations Thank you, Latanya. Good afternoon, and welcome to Puma's conference call to discuss our earnings results for the third quarter of 2026. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President, and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial Officer; Heather Blaber, Senior Vice President of Marketing; and Roger Storms, Senior Vice President of Sales. After the close today, Puma issued a news release detailing earnings results for the third quarter of 2026. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and Investor section of our website at pumabiotechnology.com. The webcast and presentation slides will be archived on our website and available for replay for the next 90 days. Today's conference call will include statements about Puma's future expectations, plans, and prospects that constitute forward-looking statements for purposes of federal securities laws. Such statements are subject to risks and uncertainties, and actual events and results may differ from those expressed in these forward-looking statements. For a full discussion of these risks and uncertainties, please review our periodic and current reports filed with the SEC from time to time, including our annual report on Form 10-K for the year ended December 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this live conference call, November 5, 2026. Puma undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, we may refer to certain non-GAAP financial measures that involve adjustments to our GAAP figures. We believe these non-GAAP metrics may be useful to investors as a supplement to, but not a substitute for, our GAAP financial measures. Please refer to our third quarter 2026 earnings release for a reconciliation of our GAAP to non-GAAP results. I will now turn the call over to Alan.

    Alan Auerbach CEO, President, and Chairman of the Board Thank you, Mariann, and thank you all for joining our call today. Today, Puma reported total revenue for the third quarter of 2026 of $55.1 million. Total revenue includes product revenue net, which consists entirely of NERLYNX sales, as well as royalties from our sub-licensees. Product revenue net was $54.1 million in the third quarter of 2026, an increase from $53.6 million reported in Q2 2026 and $51.9 million reported in Q3 2025. As a reminder to investors, Puma reported NERLYNX sales includes both U.S. net sales of NERLYNX and product supply revenues of NERLYNX to Puma's ex-U.S. partners.

    Frequently Asked Questions About PBYI

    When is Puma Biotechnology's next earnings date?

    Puma Biotechnology's next earnings report is expected for Feb 24, 2027.

    Did PBYI beat earnings estimates last quarter?

    Yes. Puma Biotechnology reported EPS of $0.11 for the quarter ended Sep 30, 2026, above the $0.06 estimate, a 83.33% surprise.

    What EPS do analysts expect from PBYI next quarter?

    The consensus EPS estimate for Puma Biotechnology for the quarter ending Dec 31, 2026 is $0.23 from 3 analysts, with estimates from $0.23 to $0.24.

    How often does PBYI beat earnings estimates?

    Puma Biotechnology beat the EPS estimate in each of the last 11 quarters, with an average surprise of +116.51%.